Generic Jentadueto XR Availability
Last updated on Jun 11, 2025.
See also: Generic Jentadueto
Jentadueto XR is a brand name of linagliptin/metformin, approved by the FDA in the following formulation(s):
JENTADUETO XR (linagliptin; metformin hydrochloride - tablet, extended release;oral)
-
Manufacturer: BOEHRINGER INGELHEIM
Approval date: May 27, 2016
Strength(s): 2.5MG;1GM [RLD], 5MG;1GM [RLD]
Is there a generic version of Jentadueto XR available?
No. There is currently no therapeutically equivalent version of Jentadueto XR available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Jentadueto XR. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
Patent 10,022,379
Issued: July 17, 2018
Inventor(s): Friedl Thomas & Braun Michael & Egusa Kenji & Fujita Hikaru & Maruyama Megumi & Nishioka Takaaki
Assignee(s): Boehringer Ingelheim International GmbHThe present invention relates to pharmaceutical compositions comprising fixed dose combinations of a DPP-4 inhibitor drug and a partner drug, processes for the preparation thereof, and their use to treat certain diseases.
Patent expiration dates:
- April 2, 2029✓
- April 2, 2029
-
DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
Patent 10022379*PE
Issued: July 17, 2018
Inventor(s): Friedl Thomas & Braun Michael & Egusa Kenji & Fujita Hikaru & Maruyama Megumi & Nishioka Takaaki
Assignee(s): Boehringer Ingelheim International GmbHThe present invention relates to pharmaceutical compositions comprising fixed dose combinations of a DPP-4 inhibitor drug and a partner drug, processes for the preparation thereof, and their use to treat certain diseases.
Patent expiration dates:
- October 2, 2029
- October 2, 2029
-
Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug
Patent 11,911,388
Issued: February 27, 2024
Inventor(s): Graefe-Mody; Eva Ulrike et al.
Assignee(s): Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE)The present invention relates to the finding that certain DPP-4 inhibitors are particularly suitable for treating and/or preventing metabolic diseases, particularly diabetes, in patients with insufficient glycemic control despite a therapy with an oral and/or a non-oral antidiabetic drug.
Patent expiration dates:
- April 10, 2030✓
- April 10, 2030
-
8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
Patent 7,407,955
Issued: August 5, 2008
Inventor(s): Himmelsbach; Frank et al.
Assignee(s): Boehringer Ingelheim Pharma GmbH & Co., KG (Ingelheim, DE)The present invention relates to substituted xanthines of general formula ##STR00001## wherein R.sup.1 to R.sup.3 are defined as in claims 1 to 16, the tautomers, the stereoisomers, the mixtures, the prodrugs thereof and the salts thereof which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).
Patent expiration dates:
- May 2, 2025✓✓
- May 2, 2025
-
8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
Patent 7407955*PED
Issued: August 5, 2008
Inventor(s): Himmelsbach; Frank et al.
Assignee(s): Boehringer Ingelheim Pharma GmbH & Co., KG (Ingelheim, DE)The present invention relates to substituted xanthines of general formula ##STR00001## wherein R.sup.1 to R.sup.3 are defined as in claims 1 to 16, the tautomers, the stereoisomers, the mixtures, the prodrugs thereof and the salts thereof which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).
Patent expiration dates:
- November 2, 2025✓
- November 2, 2025
-
Uses of DPP-IV inhibitors
Patent 8,673,927
Issued: March 18, 2014
Inventor(s): Dugi Klaus & Himmelsbach Frank & Mark Michael
Assignee(s): Boehringer Ingelheim International GmbHThe specification describes the use of selected DPP IV inhibitors for the treatment of physiological functional disorders and for reducing the risk of the occurrence of such functional disorders in at-risk patient groups. In addition, the use of the above-mentioned DPP IV inhibitors in conjunction with other active substances is described, by means of which improved treatment outcomes can be achieved. These applications may be used to prepare corresponding medicaments.
Patent expiration dates:
- May 4, 2027✓✓
- May 4, 2027
-
Uses of DPP-IV inhibitors
Patent 8673927*PED
Issued: March 18, 2014
Inventor(s): Dugi Klaus & Himmelsbach Frank & Mark Michael
Assignee(s): Boehringer Ingelheim International GmbHThe specification describes the use of selected DPP IV inhibitors for the treatment of physiological functional disorders and for reducing the risk of the occurrence of such functional disorders in at-risk patient groups. In addition, the use of the above-mentioned DPP IV inhibitors in conjunction with other active substances is described, by means of which improved treatment outcomes can be achieved. These applications may be used to prepare corresponding medicaments.
Patent expiration dates:
- November 4, 2027✓
- November 4, 2027
-
Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines
Patent 8,883,805
Issued: November 11, 2014
Inventor(s): Pfrengle Waldemar & Pachur Thorsten & Nicola Thomas & Duran Adil
Assignee(s): Boehringer Ingelheim International GmbHThe invention relates to an improved process for preparing enantiomerically pure 8-(3-aminopiperidin-1-yl)-xanthines.
Patent expiration dates:
- November 26, 2025✓
- November 26, 2025
-
Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines
Patent 8883805*PED
Issued: November 11, 2014
Inventor(s): Pfrengle Waldemar & Pachur Thorsten & Nicola Thomas & Duran Adil
Assignee(s): Boehringer Ingelheim International GmbHThe invention relates to an improved process for preparing enantiomerically pure 8-(3-aminopiperidin-1-yl)-xanthines.
Patent expiration dates:
- May 26, 2026✓
- May 26, 2026
-
DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
Patent 9,155,705
Issued: October 13, 2015
Inventor(s): Friedl Thomas & Braun Michael & Egusa Kenji & Fujita Hikaru & Maruyama Megumi & Nishioka Takaaki
Assignee(s): Boehringer Ingelheim International GmbHThe present invention relates to pharmaceutical compositions comprising fixed dose combinations of a DPP-4 inhibitor drug and a partner drug, processes for the preparation thereof, and their use to treat certain diseases.
Patent expiration dates:
- May 21, 2030✓
- May 21, 2030
-
DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
Patent 9155705*PED
Issued: October 13, 2015
Inventor(s): Friedl Thomas & Braun Michael & Egusa Kenji & Fujita Hikaru & Maruyama Megumi & Nishioka Takaaki
Assignee(s): Boehringer Ingelheim International GmbHThe present invention relates to pharmaceutical compositions comprising fixed dose combinations of a DPP-4 inhibitor drug and a partner drug, processes for the preparation thereof, and their use to treat certain diseases.
Patent expiration dates:
- November 21, 2030✓
- November 21, 2030
-
Uses of DPP IV inhibitors
Patent 9,173,859
Issued: November 3, 2015
Inventor(s): Dugi Klaus & Himmelsbach Frank & Mark Michael
Assignee(s): Boehringer Ingelheim International GmbHThe specification describes the use of selected DPP IV inhibitors for the treatment of physiological functional disorders and for reducing the risk of the occurrence of such functional disorders in at-risk patient groups. In addition, the use of the above-mentioned DPP IV inhibitors in conjunction with other active substances is described, by means of which improved treatment outcomes can be achieved. These applications may be used to prepare corresponding medicaments.
Patent expiration dates:
- May 4, 2027✓✓✓
- May 4, 2027
-
Uses of DPP IV inhibitors
Patent 9173859*PED
Issued: November 3, 2015
Inventor(s): Dugi Klaus & Himmelsbach Frank & Mark Michael
Assignee(s): Boehringer Ingelheim International GmbHThe specification describes the use of selected DPP IV inhibitors for the treatment of physiological functional disorders and for reducing the risk of the occurrence of such functional disorders in at-risk patient groups. In addition, the use of the above-mentioned DPP IV inhibitors in conjunction with other active substances is described, by means of which improved treatment outcomes can be achieved. These applications may be used to prepare corresponding medicaments.
Patent expiration dates:
- November 4, 2027✓
- November 4, 2027
-
DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
Patent 9,415,016
Issued: August 16, 2016
Inventor(s): Friedl Thomas & Braun Michael & Egusa Kenji & Fujita Hikaru & Maruyama Megumi & Nishioka Takaaki
Assignee(s): Boehringer Ingelheim International GmbHThe present invention relates to pharmaceutical compositions comprising fixed dose combinations of a DPP-4 inhibitor drug and a partner drug, processes for the preparation thereof, and their use to treat certain diseases.
Patent expiration dates:
- April 2, 2029✓
- April 2, 2029
-
DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
Patent 9415016*PED
Issued: August 16, 2016
Inventor(s): Friedl Thomas & Braun Michael & Egusa Kenji & Fujita Hikaru & Maruyama Megumi & Nishioka Takaaki
Assignee(s): Boehringer Ingelheim International GmbHThe present invention relates to pharmaceutical compositions comprising fixed dose combinations of a DPP-4 inhibitor drug and a partner drug, processes for the preparation thereof, and their use to treat certain diseases.
Patent expiration dates:
- October 2, 2029✓
- October 2, 2029
-
Pharmaceutical composition and uses thereof
Patent 9,555,001
Issued: January 31, 2017
Inventor(s): Ito Masanori & Egusa Kenji & Kleinbeck Kyle & Messerschmid Roman & Schneider Peter & Voleti Venkata
Assignee(s): Boehringer Ingelheim International GmbHThe present invention relates to pharmaceutical compositions comprising fixed dose combinations of a DPP-4 inhibitor drug and/or a SGLT-2 inhibitor drug, and metformin XR, processes for the preparation thereof, and their use to treat certain diseases.
Patent expiration dates:
- March 6, 2033✓✓
- March 6, 2033✓✓
- March 6, 2033
-
Pharmaceutical composition and uses thereof
Patent 9555001*PED
Issued: January 31, 2017
Inventor(s): Ito Masanori & Egusa Kenji & Kleinbeck Kyle & Messerschmid Roman & Schneider Peter & Voleti Venkata
Assignee(s): Boehringer Ingelheim International GmbHThe present invention relates to pharmaceutical compositions comprising fixed dose combinations of a DPP-4 inhibitor drug and/or a SGLT-2 inhibitor drug, and metformin XR, processes for the preparation thereof, and their use to treat certain diseases.
Patent expiration dates:
- September 6, 2033✓
- September 6, 2033
Related exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- June 20, 2026 - REVISIONS TO THE PEDIATRIC USE SUBSECTION OF LABELING TO INCLUDE THE RESULTS FROM CLINICAL STUDY 1218-0091, CONDUCTED TO FULFILL A PEDIATRIC WRITTEN REQUEST
- December 20, 2026 - PEDIATRIC EXCLUSIVITY
More about Jentadueto XR (linagliptin / metformin)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (2)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- Drug class: antidiabetic combinations
- En español
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
Related/similar drugs
Trulicity
Trulicity is an injectable diabetes medicine that is used together with diet and exercise to ...
Lantus
Lantus is a long acting form of insulin used to treat type 1 or type 2 diabetes. Learn about side ...
Ozempic
Learn about Ozempic (semaglutide) for type 2 diabetes treatment, weight management, cardiovascular ...
Tresiba
Tresiba (insulin degludec) is used to treat diabetes mellitus. Includes Tresiba side effects ...
Levemir
Levemir (insulin detemir) is a long acting insulin used to treat diabetes in adults and children ...
Victoza
Victoza helps control blood sugar levels and reduce the risk of serious heart problems in people ...
Novolog
NovoLog is a fast-acting insulin used to treat diabetes to control blood sugar levels in adults and ...
Basaglar
Basaglar (insulin glargine) is a long-acting insulin that is used to improve blood sugar control in ...
Soliqua
Soliqua 100/33 (insulin glargine and lixisenatide) is used to treat type 2 diabetes. Includes ...
Toujeo SoloStar
Toujeo (insulin glargine) is an injection used to treat type 1 or type 2 diabetes. Includes Toujeo ...
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
